1. Home
  2. KOSS vs BOLD Comparison

KOSS vs BOLD Comparison

Compare KOSS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koss Corporation

KOSS

Koss Corporation

HOLD

Current Price

$4.36

Market Cap

39.3M

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.56

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOSS
BOLD
Founded
1953
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
39.3M
36.5M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
KOSS
BOLD
Price
$4.36
$1.56
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
26.3K
366.0K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
10.00
32.47
EPS
N/A
N/A
Revenue
$12,624,170.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.93
N/A
52 Week Low
$3.50
$0.96
52 Week High
$8.59
$1.72

Technical Indicators

Market Signals
Indicator
KOSS
BOLD
Relative Strength Index (RSI) 57.21 61.19
Support Level $4.16 $1.12
Resistance Level $4.91 $1.55
Average True Range (ATR) 0.27 0.08
MACD 0.01 -0.01
Stochastic Oscillator 47.62 52.17

Price Performance

Historical Comparison
KOSS
BOLD

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: